Within 1 year prior to the baseline visit with any live bacterial therapy.Within16 weeks or 5 half-lives, whichever is longer, prior to the baseline visit with dupilumab or other biologic agent to treat atopic dermatitis.Within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the baseline visit with Janus kinase inhibitors or other investigational drug.Use of emollients other than provided for the study.Topical phosphodiesterase type 4 (PDE4) inhibitor.Topical corticosteroids (does not include inhaled, intranasal or ophthalmic) or topical calcineurin inhibitors.Previous treatment within 1 week prior to the baseline visit with any of the following:.Phototherapy or photo chemotherapy for atopic dermatitis.Immunosuppressive or immunomodulating systemic drugs such as systemic (intravenous, oral, intra-articular or intramuscular) corticosteroids, azathioprine, methotrexate, cyclosporine.Previous treatment within 4 weeks prior to the baseline visit with any of the following:.5% to 30% (inclusive) body surface area of atopic dermatitis involvement at the screening and the baseline visit.EASI score ≥ 5 at the screening and the Baseline visit.Investigator Global Assessment (IGA) score of 2 (mild) or 3 (moderate) at Screening and Baseline/Day 1 using the validated IGA scale for atopic dermatitis.Clinical diagnosis of atopic dermatitis as defined by Hanifin and Rajka criteria that has been present for ≥ 3 months before the screening visit.Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |